Four years ago, we set out to change how cancer is treated. What began with a breakthrough discovery on CD24 is now a clinical-stage effort advancing macrophage-directed therapies that help the immune system “feast” on cancer.

Thank you to all who support us on our mission!

The crew that sails together, prevails together. This summer, the Pheast team set sail for a day on the water – building trust, sharing laughs, and celebrating the spirit of collaboration that drives us.

#PheastMode

This #PrideMonth, our team gathered to reflect, create, and celebrate. We’re proud to stand with the LGBTQIA+ community, within our walls and beyond, and to take action toward equity.

#Pride2025

We moved! As the Pheast team settles into our new space, we’re inspired by what drives us: a trailblazing spirit, empowered teams, and a passion for improving lives through science. Here’s to progress powered by purpose, rigor, and bold ideas.

#PheastMode

We’re not just developing a new drug—we’re opening the door to an entirely new immune mechanism. Pheast CEO Roy Maute talks with 𝗕𝗮𝘀𝗲 𝘁𝗼 𝗕𝗮𝘀𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗣𝗼𝗱𝗰𝗮𝘀𝘁 about macrophages, CD24, and our first clinical trial.

deeptechdigest.com/biotech/base...